Literature DB >> 33982290

Epigenetic regulation of epithelial dectin-1 through an IL-33-STAT3 axis in allergic disease.

Hwan Mee Yong1,2, Naina Gour3, Deepika Sharma1, Syed Muaz Khalil1, Andrew P Lane3, Stephane Lajoie1,2.   

Abstract

Allergic diseases arise in susceptible individuals in part because of decrements in protective pathways. The mechanism by which these anti-inflammatory molecules become repressed remains unclear. We have previously reported that epithelial dectin-1 prevents aberrant type 2 responses and is downregulated in the epithelium of allergic patients. Here, we report that dectin-1 is constitutively expressed by the respiratory epithelium in humans and that IL-33 specifically acts as a repressor of dectin-1. Mechanistically, this occurs via IL-33-dependent STAT3 activation and the subsequent repression of the dectin-1 gene, CLEC7A. We have identified a novel enhancer region upstream of the proximal promoter of CLEC7A that is only accessible in epithelial cells, but not in hematopoietic cells. Epigenetic repression of CLEC7A through this newly identified locus, downstream of an aberrant IL-33-STAT3 axis, occurs in the epithelium of allergic individuals. Collectively, our data identify a mechanism of epigenetic fine-tuning of dectin-1 expression in epithelial cells that may participate in allergenicity.
© 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Entities:  

Keywords:  IL-33; allergic diseases; allergy; dectin-1; epithelium

Mesh:

Substances:

Year:  2021        PMID: 33982290     DOI: 10.1111/all.14898

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  2 in total

Review 1.  Emerging roles of Dectin-1 in noninfectious settings and in the CNS.

Authors:  M Elizabeth Deerhake; Mari L Shinohara
Journal:  Trends Immunol       Date:  2021-09-04       Impact factor: 19.709

Review 2.  Dectin-1 Signaling Update: New Perspectives for Trained Immunity.

Authors:  Pablo Mata-Martínez; Marta Bergón-Gutiérrez; Carlos Del Fresno
Journal:  Front Immunol       Date:  2022-02-14       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.